Purpose

The primary objective of this study is to evaluate the real-world performance of the CoreValve Evolut PRO transcatheter aortic valve, including leaflet function, in a prospective observational registry.

Condition

Eligibility

Eligible Ages
Over 50 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Symptomatic severe aortic stenosis 2. Intermediate, high or extreme surgical risk 3. The institutional Heart Team determines that transcatheter aortic valve replacement with an Evolut Pro device is appropriate

Exclusion Criteria

  1. Subject unable or unwilling to give informed consent 2. For subjects in the CT arm only, renal function precluding the administration of iodinated contrast for cardiac CT (eGFR < 30 ml/min/1.73m2). An exception to this exclusion criterion is made if the subject is established on renal replacement therapy and is therefore able to receive intravenous iodinated contrast media. 3. Pregnancy or intent to become pregnant prior to completion of all protocol follow-up procedures

Study Design

Phase
Study Type
Observational [Patient Registry]
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
CT Cohort Compare the rate of ≥mild PVL in patients with none/mild versus moderate/severe LVOT calcification. Comparison of the rate of PPM implantation in patients with none/mild versus moderate/severe LVOT calcification. Determine how the Evolut PRO conforms to LVOT calcification. Compare the impact of LVOT calcification on the implantation depth of the Evolut PRO. Analyze the interaction and geometry of the Evolut PRO in patients with moderate/severe LVOT calcification. Assess for leaflet thickening, subclinical leaflet thrombosis and/or restricted leaflet motion 30-60 days after TAVR.
  • Device: TAVR
    Transcatheter Aortic Valve Replacement
Non-CT Cohort Compare the rate of ≥mild PVL with the Evolut PRO with a propensity score matched cohort of historical control subjects who underwent TAVR with the Evolut R and/or CoreValve within the MedStar Health System. Determine which features of LVOT calcification (volume, location relative to aortic annulus and sinuses, prominence into the LVOT lumen) predict ≥mild PVL. Determine which features of LVOT calcification (volume, location relative to aortic annulus and sinuses, prominence into the LVOT lumen) predict PPM implantation.
  • Device: TAVR
    Transcatheter Aortic Valve Replacement

Recruiting Locations

MedStar Washington Hospital Center
Washington, District of Columbia 20010
Contact:
Megan Rowland, MPH
202-877-2959
megan.e.rowland@medstar.net

Medstar Union Memorial Hospital
Baltimore, Maryland 21218
Contact:
John Wang
410-554-2332

More Details

Status
Recruiting
Sponsor
Medstar Health Research Institute

Study Contact

Megan Rowland, MPH
202-877-2959
megan.e.rowland@medstar.net

Detailed Description

The CoreValve Evolut PRO transcatheter aortic valve was approved by the FDA in March 2017 to treat patients with symptomatic severe aortic stenosis at high or extreme risk for open heart surgery, and in July 2017 for intermediate risk patients. This latest generation device features an outer wrap to improve annular sealing and reduce paravalvular leak. In this observational study, baseline demographic and imaging characteristics, procedural details and clinical outcomes of patients undergoing transcatheter aortic valve replacement with the CoreValve Evolut PRO will be prospectively collected into a registry database. The institutional Heart Team will select patients according to standard practice.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.